Physician profile
Kurt Blake
NPI 1265964803
$7,147.88
in general payments reported to CMS, 2019-2025
30 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $943 · 2023: $2,118 · 2024: $2,326 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,110 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,110.18 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,467.52 | 2022-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,023.47 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $984.72 | 2022-2025 | Enbrel, Tavneos, Otezla |
| Astrazeneca Pharmaceuticals LP | $963.08 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $573.97 | 2023-2025 | |
| Glaxosmithkline, LLC. | $493.26 | 2022-2025 | Benlysta |
| Genzyme Corporation | $259.20 | 2022-2024 | |
| Ucb, INC. | $245.36 | 2022-2025 | Bimzelx, Cimzia |
| Progentec Diagnostics, INC. | $243.39 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.26 | 2023-2025 | Ofev, Spevigo |
| Horizon Therapeutics Plc | $93.21 | 2022-2023 | Krystexxa |
| Genentech USA, INC. | $72.06 | 2024-2025 | Actemra, Gazyva |
| Alexion Pharmaceuticals, INC. | $61.19 | 2023 | Ultomiris |
| Daiichi Sankyo INC. | $53.65 | 2022 | |
| Pfizer INC. | $44.61 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $39.36 | 2022 | |
| Sk Life Science, INC. | $29.66 | 2022 | |
| Aurinia Pharma U.S., INC. | $28.30 | 2024 | Lupkynis |
| Fresenius Kabi USA, LLC | $27.18 | 2023-2024 | Idacio |
| Blueprint Medicines Corporation | $24.92 | 2024 | Ayvakit |
| Sobi, INC | $23.15 | 2025 | |
| Sandoz INC. | $21.37 | 2023 | Hyrimoz |
| Lilly USA, LLC | $18.99 | 2022 | |
| Radius Health, INC. | $18.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.05 | 2022 | |
| Acorda Therapeutics, INC | $17.93 | 2023 | Inbrija |
| Teva Pharmaceuticals USA, INC. | $17.09 | 2023 | Austedo |
| Kyowa Kirin, INC. | $15.60 | 2025 | |
| Atland Pharmaceuticals, LLC | $14.38 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| E.R. Squibb & Sons, L.L.C. | $14.34 | 2025 | Orencia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.